CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 10.5

ph-index = 2

Forward Citations = 14(Granted Patents)

Company Filing History:

8 out of 25

Legochem Biosciences, Inc.

patents

4 out of 4

Legochem Bioscience Ltd.

patents

2 out of 260

The Green Cross Corporation

patents

where one patent can have more than one assignee

Years Active: 2012-2019

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10273235 - Compositions and methods for inhibiting β-lactamase (2019-04-30),

2. 9988372 - Crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition comprising same (2018-06-05),

3. 9951072 - Compositions and methods for inhibiting beta-lactamase (2018-04-24),

4. 9630977 - Cephalosporin derivatives and pharmaceutical compositions thereof (2017-04-25),

5. 8846669 - Oxazolidinone derivative and medical composition containing same (2014-09-30),

6. 8754210 - Method for preparing 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl) derivative and intermediate used therein (2014-06-17),

7. 8703939 - Method for preparing (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(substituted methyl)oxazolidin-2-one derivatives (2014-04-22),

8. 8637667 - Method for preparing (S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide derivatives (2014-01-28),

9. 8329684 - Cephalosporin derivatives and pharmaceutical compositions thereof (2012-12-11),

10. 8288423 - FXa inhibitors with cyclic amidines as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof (2012-10-16),

11. 8242113 - Oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone pharmaceutical compositions thereof (2012-08-14),

12. 8178525 - FXA inhibitors with cyclic amidoxime or cyclic amidrazone as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof (2012-05-15),

Title: Young Lag Cho: Innovator in Pharmaceutical Sciences

Introduction

Young Lag Cho is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of novel compounds and methods for medical applications. With a total of 12 patents to his name, Cho's work has the potential to impact various therapeutic areas.

Latest Patents

Among his latest patents, Cho has developed compositions and methods for inhibiting β-lactamase. This includes substituted dihydroisoxazole derivatives that serve as effective inhibitors of β-lactamases, which are crucial in combating antibiotic resistance. Another notable patent involves a crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate. This invention demonstrates excellent stability in high-temperature and humidity environments, making it suitable for treating various diseases, including thrombosis and myocardial infarction.

Career Highlights

Young Lag Cho has worked with reputable companies such as Legochem Biosciences, Inc. and Legochem Bioscience Ltd. His experience in these organizations has allowed him to refine his skills and contribute to innovative research in the pharmaceutical sector.

Collaborations

Throughout his career, Cho has collaborated with notable colleagues, including Yong Zu Kim and Tae Kyo Park. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking inventions.

Conclusion

Young Lag Cho's contributions to pharmaceutical innovations highlight his role as a key inventor in the field. His patents reflect a commitment to addressing critical health challenges through scientific advancements.

This text is generated by artificial intelligence and may not be accurate.